In consistent with other reports, our previous study revealed that PI3K/AKT was mostly regulated in sorafenib-resistant cells using RNA-sequencing [15] and concomitantly enhanced GSK3β/β-catenin signaling [21, 25, 32], suggesting that AKT activation increases the stemness of HCC cells. The gene discussed is AKT1; the disease is hepatocellular carcinoma.